Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14

被引:53
作者
Blagg, JA [1 ]
Noe, MC [1 ]
Wolf-Gouveia, LA [1 ]
Reiter, LA [1 ]
Laird, ER [1 ]
Chang, SPP [1 ]
Danley, D [1 ]
Downs, JT [1 ]
Elliott, NC [1 ]
Eskra, JD [1 ]
Griffiths, RJ [1 ]
Hardink, JR [1 ]
Haugeto, AI [1 ]
Jones, CS [1 ]
Liras, JL [1 ]
Lopresti-Morrow, LL [1 ]
Mitchell, PG [1 ]
Pandit, J [1 ]
Robinson, RP [1 ]
Subramanyam, C [1 ]
Vaughn-Bowser, ML [1 ]
Yocum, SA [1 ]
机构
[1] Pfizer Inc, Global Res & Dev, Groton Labs, Groton, CT 06340 USA
关键词
MMP-13; matrix metalloproteinase; osteoarthritis;
D O I
10.1016/j.bmcl.2005.02.038
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
Through the use of computational modeling, a series of pyrimidinetrione-based inhibitors of MMP-13 was designed based on a lead inhibitor identified through file screening. Incorporation of a biaryl ether moiety at the C-5 position of the pyrimidinetrione ring resulted in a dramatic enhancement of MMP-13 potency. Protein crystallography revealed that this moiety binds in the S-I' pocket of the enzyme. Optimization of the C-4 substituent of the terminal aromatic ring led to incorporation of selectivity versus MMP-14 (MT-1 NIMP). Structure activity relationships of the biaryl ether substituent are presented as is pharmacokinetic data for a compound that meets our in vitro potency and selectivity goals. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1807 / 1810
页数:4
相关论文
共 18 条
[1]
A HIGH-THROUGHPUT FLUOROGENIC SUBSTRATE FOR INTERSTITIAL COLLAGENASE (MMP-1) AND GELATINASE (MMP-9) [J].
BICKETT, DM ;
GREEN, MD ;
BERMAN, J ;
DEZUBE, M ;
HOWE, AS ;
BROWN, PJ ;
ROTH, JT ;
MCGEEHAN, GM .
ANALYTICAL BIOCHEMISTRY, 1993, 212 (01) :58-64
[2]
The 1.8-Å crystal structure of a matrix metallaproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition [J].
Brandstetter, H ;
Grams, F ;
Glitz, D ;
Lang, A ;
Huber, R ;
Bode, W ;
Krell, HW ;
Engh, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (20) :17405-17412
[3]
Metalloproteinases: their role in arthritis and potential as therapeutic targets [J].
Clark, IM ;
Parker, AE .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (01) :19-34
[4]
X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin [J].
Dunten, P ;
Kammlott, U ;
Crowther, R ;
Levin, W ;
Foley, LH ;
Wang, P ;
Palermo, R .
PROTEIN SCIENCE, 2001, 10 (05) :923-926
[5]
Novel 5,5-disubstitutedpyrimidine-2,4,6-trione as selective MMP inhibitors [J].
Foley, LH ;
Palermo, R ;
Dunten, P ;
Wang, P .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (08) :969-972
[6]
Pyrimidine-2,4,6-triones:: A new effective and selective class of matrix metalloproteinase inhibitors [J].
Grams, F ;
Brandstetter, H ;
D'Alò, S ;
Geppert, D ;
Krell, HW ;
Leinert, H ;
Livi, V ;
Menta, E ;
Oliva, A ;
Zimmermann, G .
BIOLOGICAL CHEMISTRY, 2001, 382 (08) :1277-1285
[7]
Griffioen A W, 2000, IDrugs, V3, P336
[8]
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover [J].
Holmbeck, K ;
Bianco, P ;
Caterina, J ;
Yamada, S ;
Kromer, M ;
Kuznetsov, SA ;
Mankani, M ;
Robey, PG ;
Poole, AR ;
Pidoux, I ;
Ward, JM ;
Birkedal-Hansen, H .
CELL, 1999, 99 (01) :81-92
[9]
Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor [J].
Hutchinson, JW ;
Tierney, GM ;
Parsons, SL ;
Davis, TRC .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1998, 80B (05) :907-908
[10]
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13) [J].
Kim, SH ;
Pudzianowski, AT ;
Leavitt, KJ ;
Barbosa, J ;
McDonnell, PA ;
Metzler, WJ ;
Rankin, BM ;
Liu, R ;
Vaccaro, W ;
Pitts, W .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (04) :1101-1106